Subcutaneous administration of Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 29, Issue 2, 2009, Pages 199-203

  Fang, Yu Wei ^a   Chang, Chung Hsin ^a,b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; End stage renal disease; Erythropoietin

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON POLYMALTOSE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; MEAN CORPUSCULAR VOLUME; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE INDICES; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 67149105612     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900215     Document Type: Article

References (17)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316:73-8.
2. Bommer J, Barth HP, Zeier M, Mandelbaum A, Bommer G, Ritz E, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-43.
3. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case of subcutaneous administration. J Am Soc Nephrol 1992; 2:1405-16.
4. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339:578-83.
5. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(Suppl 3):3-13.
6. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Horl WH, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16(Suppl 3):22-8.
7. Macdougall IC. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl 2002; 80:55-61.
8. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs 2005; 19:327-43.
9. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al. Novel erythropoiesis stimulating protein for the treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60:741-7.
10. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62:2167-75.
11. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40:110-18.
12. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18:362-9.
13. Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003; 18: 576-81.
14. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004; 19:1224-30.
15. Mahajan S, Boulton H, Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004; 17:687-92.
16. Grzeszczak W, Sulowicz W, Rutkowski B, Vecchi AF, Scanziani R, Durand PY, et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anemia. Nephrol Dial Transplant 2005; 20:936-44.
17. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2006; 21:2846-50.